StreetInsider.com News Articles

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Wed, 04 Mar 2026 16:05:00 -0500

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET.

A live webcast of Ironwood’s fireside chat will be accessible through the Investors & Media section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases.

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Wed, 04 Mar 2026 16:05:00 -0500

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases.

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Wed, 04 Mar 2026 16:05:00 -0500

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases.

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Wed, 04 Mar 2026 16:05:00 -0500

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases.

Form 10-K IRONWOOD PHARMACEUTICALS For: Dec 31

Thu, 26 Feb 2026 16:13:00 -0500

si-local-file:///var/storage/secattach/20260226/26070769.html

Form 10-K IRONWOOD PHARMACEUTICALS For: Dec 31

Thu, 26 Feb 2026 16:13:00 -0500

si-local-file:///var/storage/secattach/20260226/26070769.html

Ironwood Pharmaceuticals (IRWD) PT Raised to $3.70 at Jefferies

Thu, 26 Feb 2026 10:35:49 -0500

Jefferies analyst Amy Li raised the price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) to $3.70 (from $0.70) while maintaining a Hold rating.

The analyst comments "IRWD’s Q4 & FY'26 guide were in line w/ preannounce. We flag: 1) STARS-2 looks like full Ph.3 & apra NDA filing will be ’29; 2) IRWD expects Linzess net sales improv in '26 post WAC reset, w/ continued growth in '27/'28 & pot'l longer LOE tail. We incr. Linzess PS to $478M & PT to $3.7. We remain Hold-rated, given limited near-term catalysts & Qs on apra's competitive positioning in an increasingly competitive SBS-IF market

Ironwood Pharmaceuticals (IRWD) PT Raised to $3.70 at Jefferies

Thu, 26 Feb 2026 10:35:49 -0500

Jefferies analyst Amy Li raised the price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) to $3.70 (from $0.70) while maintaining a Hold rating.

Ironwood Pharmaceuticals (IRWD) PT Raised to $10 at Citizens: Cash-Flow Generation Likely

Thu, 26 Feb 2026 04:45:01 -0500

Citizens analyst Jason Butler raised the price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) to $10.00 (from $8.00) while maintaining a Market Outperform rating.

The analyst commented, "2026 guidance reiterated as we remain confident in LINZESS cash-flow generation; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $10 from $8 on Ironwood Pharmaceuticals. Ironwood reported 4Q25 financial results consistent with prior guidance and more importantly reiterated 2026 guidance including adjusted EBITDA >$300MM. Management expects to substantially lower its outstanding debt principals in 2026 and end the year with ~$300MM outstanding (1x adjusted EBITDA leverage). We continue to

Ironwood Pharmaceuticals (IRWD) PT Raised to $10 at Citizens: Cash-Flow Generation Likely

Thu, 26 Feb 2026 04:45:01 -0500

Citizens analyst Jason Butler raised the price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) to $10.00 (from $8.00) while maintaining a Market Outperform rating.

Form 4 IRONWOOD PHARMACEUTICALS For: Feb 23 Filed by: John Minardo

Wed, 25 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260225/26059785.html

Form 4 IRONWOOD PHARMACEUTICALS For: Feb 23 Filed by: John Minardo

Wed, 25 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260225/26059785.html

Form 4 IRONWOOD PHARMACEUTICALS For: Feb 23 Filed by: Shetzline Michael

Wed, 25 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260225/26059793.html

Form 4 IRONWOOD PHARMACEUTICALS For: Feb 23 Filed by: Shetzline Michael

Wed, 25 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260225/26059793.html

Form 4 IRONWOOD PHARMACEUTICALS For: Feb 23 Filed by: Silver Ronald